Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Accumulated Expenses (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Accumulated Expenses over the past 15 years, most recently at $22.0 million for Q2 2025.

  • Quarterly results put Accumulated Expenses at $22.0 million for Q2 2025, down 2.57% from a year ago — trailing twelve months through May 2025 was $22.0 million (down 2.57% YoY), and the annual figure for FY2025 was $22.0 million, down 2.57%.
  • Accumulated Expenses for Q2 2025 was $22.0 million at Lifecore Biomedical, Inc. \De\, up from $19.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for LFCR hit a ceiling of $22.5 million in Q2 2024 and a floor of $3.3 million in Q4 2021.
  • Median Accumulated Expenses over the past 5 years was $5.7 million (2022), compared with a mean of $8.2 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 53.64% in 2023 and later soared 443.74% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Accumulated Expenses stood at $3.3 million in 2021, then increased by 26.04% to $4.1 million in 2022, then decreased by 18.27% to $3.4 million in 2023, then skyrocketed by 38.07% to $4.6 million in 2024, then surged by 374.15% to $22.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $22.0 million (Q2 2025), $19.7 million (Q1 2025), and $4.6 million (Q4 2024) per Business Quant data.